Hyperfine (HYPR) said Tuesday it has agreed to sell about 4.5 million shares along with warrants to purchase up to approximately 4.5 million shares at a price of $1.33 per share-and-warrant pair in a registered direct offering.
The health technology company said gross proceeds are expected to total $6.0 million once the offering closes Wednesday.
Hyperfine said it plans to use net proceeds for working capital and general corporate purposes.
Shares of the company were down more than 14% in Tuesday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。